SARA CARLOUGH: Open Payments
NPI 1043861503 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$554 in 17 payments from 9 companies in 2025. Trend: 2023 $401 · 2024 $410 · 2025 $554
Food & beverage: $474Education: $80
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $205 |
| Syndax Pharmaceuticals, Inc. | 3 | $91 |
| Celgene Corporation | 2 | $63 |
| ABBVIE INC. | 2 | $59 |
| SOBI, INC | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| GENZYME CORPORATION | 1 | $27 |
| Teleflex LLC | 1 | $25 |
| Incyte Corporation | 1 | $21 |
Products named: Cresemba, REBLOZYL, Vonjo, EPKINLY, ICLUSIG, AYVAKIT, VENCLEXTA, ARROW.
Industry payments across TX — which companies pay providers there.
